No abstract available.
Insulin-Like Growth Factor I*

The thyroid gland is an interesting endocrine organ where a spectrum of tumors with different behavior arise. At one end of spectrum there is differentiated thyroid carcinoma (DTC) with excellent prognosis, whereas at the other end of the spectrum is anaplastic thyroid cancer which has universally poor outcome. Radioiodine (I-131) therapy has been in use for the treatment of thyroid diseases since 1946. It was introduced by Seidlin et al. 1) Although the use of I-131 has been vouge for a long time, its use in therapy for well differentiated thyroid cancer is still controversial 2). This is because, thyroid cancers (TC) are generally slow growing tumors, with low mortality and normal spans of survival. To record recurrence and mortality, long term follow up studies over a period of two to three decades are needed to establish definite conclusions on the acceptable mode of treatment. The incidence of the disease being very low a large number of cases needed to establish a meaningful statistical data is lacking as most published reports deal with small series. Here again in the problem encountered are the differing protocols for treatment with I-131, the indications for treatment which may include or exclude ablation of residual thyroid tissue, cervical nodal and distal metastases. The dosage of I-131 used for ablation of residual thyroid tissue and metastatic disease also vary. The most reliable conclusion regarding I-131 treatment are obtained from studies reported on a large series of patients followed over a period of 2 decades or more from a single institute with a more or less unchanged protocol of management.
Follow-Up Studies ; Humans ; Incidence ; Mortality ; Neoplasm Metastasis ; Prognosis ; Recurrence ; Thyroid Diseases ; Thyroid Gland* ; Thyroid Neoplasms*

The safe clinical practice of growth hormone(GH) replacement requires judgement of the overall GH status, however, there is no biological marker for this in adults. In addition, diverse actions of GH in healthy individuals render the assessment of optimal GH replacement difficult. As in other fields of clinical practice, strategies and protocols vary between centers, however, most physicians experienced in pituitary diseases agree that GH replacement should begin at low doses, and increased to the final maintenance dose. The adequacy replacement is best determined by combination of clinical response and serum IGF-I, level avoiding supraphysiological levels of this GH-dependent peptide. Actually, GH can reduce body fat and restore muscles, bones, and quality of life. Appropriate using of GH will elicit antiaging effects.
Adipose Tissue ; Adult ; Biomarkers ; Growth Hormone* ; Humans ; Insulin-Like Growth Factor I ; Muscles ; Osteoporosis ; Pituitary Diseases ; Quality of Life

No abstract available.
Adult* ; Growth Hormone* ; Humans

No abstract available.
Cardiovascular Diseases* ; Growth Hormone*

No abstract available.
Growth Hormone

No abstract available.
Growth Hormone*

The cells of glomerular mesangium is composed mostly of intrinsic contractile mesangial cells and a few macrophages. Injury to the mesangium is central to many glomerular diseases. This study was aimed to evaluate and compare the expressions of alpha-smooth muscle actin (ASMA) and lysozyme in the mesangium of various human glomerular diseases and also of according to the severity of their progressions. We performed immunohistochemical and transmission electromicroscopic examinations in 51 cases of renal biopsy including 5 normal kidneys. The results were as follows; (1) ASMA staining was negligible in normal glomeruli. (2) Increased ASMA staining was observed in the mesangium of glomeruli from all specimens of primary glomerular disease, regardless of their diagnosis. (3) The staining intensity of ASMA in mesangium was mild in minimal change disease and membranous glomerulonephritis, and strong in focal segmental glomerulosclerosis (FSGS), diffuse mesangial hypercellularity, membranoproliferative glomerulonephritis (MPGN), and IgA nephropathy (IgAN). (4) The staining intensity of ASMA have no correlation with mesangial immune deposits. (5) The staining intensity of ASMA in mesangium was inversely correlated with the disease progression in FSGS and IgAN. (6) Glomeruli showing global or segmental sclerosis invariably lacked ASMA. (7) Compared with ASMA, the mesangial cells with lysozyme expression were very rare, even though it was in proportion to ASMA staining. Interstitial ASMA expression was confined to fibrotic area in various glomerular diseases. In conclusion, the expression of ASMA and lysozyme in mesangium are increased in a variety of glomerular diseases, regardless of disease entity. Their intensity was in proportion to the mesangial cell proliferation. In progressive glomerulonephritis, such as IgAN and FSGS, the increased expression of ASMA was prominent in the early lesion, and decreased with the progression of the glomerular sclerosis.
Actin Cytoskeleton ; Actins* ; Biopsy ; Diagnosis ; Disease Progression ; Glomerular Mesangium ; Glomerulonephritis ; Glomerulonephritis, IGA ; Glomerulonephritis, Membranoproliferative ; Glomerulonephritis, Membranous ; Glomerulosclerosis, Focal Segmental ; Humans ; Kidney ; Macrophages ; Mesangial Cells ; Muramidase* ; Muscle, Smooth* ; Nephrosis, Lipoid ; Sclerosis

No abstract available.
Korea*

Transitional cell carcinoma of the urinary bladder is the most common cancer of the urinary tract and is characterized by frequent recurrence. Like the other malignant tumor, the genetic alterations leading to neoplastic transformation of the urothelium are related with the activation of oncogenes and loss of functional tumor suppressor genes. Cyclin D1 is a putative protooncogene as cell cycle regulator essential for G1 phase progression and is frequently overexpressed in several human tumor. In this study we performed immunohistochemical stainings of cyclin D1 and p53 in both primary and recurrent transitional cell carcinomas of urinary bladder from 56 patients including 20 cases of recurrent tumor, and compared their results with histopathologic features. The results were as follows. Cyclin D1 immunoreactivity was found in 10 of 10 cases (100%) of grade 1, 25 of 41 (61%) cases of grade 2, and 11 of 25 (44%) cases of grade 3 transitional cell carcinomas. p53 immunoreactivity was found in 40% of grade 1, 63% of grade 2, and 87% of grade 3 lesions. Cyclin D1 expression was significantly higher in Ta and T1 lesions than T2 to T4 by pathologic tumor stage. Conversely p53 immunoreactivity was increased in proportion to the T classification. Cyclin D1 was de creased in recurrent transitional cell carcinomas, compared with primary transitional cell carcinomas. However, there was no statistical significance. In conclusion, cyclin D1 immunoreactivity is associated with low histologic grade and low tumor stage. And there is inverse relationship between the cyclin D1 and p53 overexpression.
Carcinoma, Transitional Cell* ; Cell Cycle ; Classification ; Cyclin D1* ; Cyclins* ; G1 Phase ; Genes, Tumor Suppressor ; Humans ; Oncogenes ; Recurrence ; Urinary Bladder* ; Urologic Neoplasms ; Urothelium